NFE2L2 and Alzheimer disease: In support of the relevance of the β-TrCP path in Nrf2 modulation in AD, it is noteworthy to mention that an increased activity of GSK-3 has been shown in patients with the disease, consistent with the decreased activation of Nrf2 observed in these cases [249,250,251,252].